Interpretation of BMP signaling in early Xenopus development  by Simeoni, I. & Gurdon, J.B.
308 (2007) 82–92
www.elsevier.com/locate/ydbioDevelopmental BiologyInterpretation of BMP signaling in early Xenopus development
I. Simeoni, J.B. Gurdon ⁎
Wellcome Trust/Cancer Research UK Gurdon Institute of Cancer and Development Biology CB2 1QN Cambridge, UK
Received for publication 23 August 2006; revised 4 May 2007; accepted 9 May 2007
Available online 18 May 2007Abstract
Very little is known about how the extracellular binding of a morphogen is transduced to the nucleus of a cell in a concentration-related way,
enabling cells to interpret their position in a concentration gradient. Here, we have analyzed when and how Xenopus embryo cells perceive and
interpret a BMP signal. Dissociated embryo cells are exposed for short times to different concentrations of BMP4. We find that cells are already
competent to receive a BMP4 signal at the blastula stage. They phosphorylate Smad1 very rapidly and express downstream genes less than half an
hour after exposure to BMP. However, Smad1 is present in the nucleus even in the absence of BMP. To quantitate intracellular signaling after BMP
exposure, we have constructed a chimeric type I receptor that registers BMP signaling as the intranuclear migration of Smad2, and as the
transcription of Smad2 downstream genes. The combination of the chimeric receptor and GFP-Smad2 makes it possible to follow the transduction
of BMP signaling to the nucleus. From our results, we conclude that an extracellular BMP concentration is interpreted by the steady state nuclear
concentration of phosphorylated Smad1.
© 2007 Elsevier Inc. All rights reserved.Keywords: BMP signaling; TGF-β; Morphogen; XenopusIntroduction
Vertebrate development depends on the action of numerous
extracellular signals that play an essential role in cell fate
determination at very early stages. It has been shown that such
signaling molecules commonly belong to the TGF-β, hedgehog
and Wnt families, and that they can act in a concentration-
dependent manner, as morphogens (Ashe and Briscoe, 2006).
Much is known about the formation of morphogen gradients,
but relatively little about how cells interpret their position in a
concentration gradient, an equally important process. Most
work on gradient interpretation in vertebrate embryos has been
carried out with the TGF-βmember activin using Xenopus cells
(Bourillot et al., 2002; Dyson and Gurdon, 1998; Green et al.,
1992; Williams et al., 2004). Another TGF-β family member,
BMP, is widely involved, often in a concentration-dependent
way, in cell fate determination at all stages of vertebrate and
invertebrate development and cell differentiation (Wilson et al.,
1997). Our aim here is to analyze how Xenopus embryo cells⁎ Corresponding author. Fax: +44 1223 334185.
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particular, we analyzed the regulation of BMP4 signaling at the
levels of receptor binding and signal transduction to the nucleus.
Gradient interpretation at the transduction level has been
analyzed in respect of activin, but signaling by BMP differs
in many respects from that of activin. Although BMP and
activin, like other members of the TGF-β family, initiate
signaling by forming a complex of two different transmembrane
serine/threonine kinase receptors (type I and type II), BMP2/4
shows receptor binding differences in comparison with other
TGF-β family members. In fact, BMP2 and BMP4 preferen-
tially bind to BMP receptor type IA (Alk3) and BMP receptor
type IB (Alk6). The resulting type I receptor–ligand complex
has high binding affinity for the BMP receptor type II. In
contrast to BMP, activin displays high affinity for the type II
receptor (ActR type IIB) allowing only subsequently the
recruitment of the receptor type I (Alk4) (Feng and Derynck,
2005; Keller et al., 2004).
The BMP receptor complex signals to the nucleus through
Smads 1, 5 and 8, in contrast to activin which signals through
Smads 2 and 3 (Miyazawa et al., 2002). Smad2 remains mainly
in the cytoplasm of a cell until activated by an activin receptor
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(Bourillot et al., 2002; Nicolas et al., 2004). In contrast, it has
been proposed that Smad1 shuttles continuously between the
nucleus and cytoplasm but spends more time in the nucleus
under conditions of BMP stimulation (Xiao et al., 2001, 2003).
In Xenopus development, BMP mRNA and protein are
concentrated in the ventral region of early embryos, where they
promote epidermal differentiation. They are present at a lower
or nil concentration in the lateral and dorsal regions that follow
cement gland or neural cell fates. BMP induces ventral
differentiation and inhibits dorsal cell fates. The downstream
genes activated by BMP in Xenopus embryos include Xvent1,
Xvent2, epidermal keratin, msx1 and Wnt8 (Gawantka et al.,
1995; Onichtchouk et al., 1996; Suzuki et al., 1997).
In our work described here, we show that Xenopus cells
become competent to receive a BMP signal at the blastula stage.
As soon as BMP is recognized at the plasma membrane, the
BMP receptor complex reads the extracellular BMP concentra-
tion and induces a proportionate amount of phosphorylated
Smad1 to migrate into the nucleus. Gene transcription reflects
quantitatively the state of Smad1 phosphorylation and occurs
immediately after cells are exposed to BMP4. Gene transcrip-
tion is maintained for up to 4 h because of the continuously
active state of the BMP receptor complex. In addition, by means
of a chimeric receptor, we have visualized and followed in real-
time when a BMP signal is present at the plasma membrane and
transduced to the nucleus in Xenopus animal cap cells.
Materials and methods
Xenopus embryo manipulation
Eggs were in vitro fertilized, dejellied and treated with 4% Ficoll
(Pharmacia) in 1X modified Barth saline (MBS) before injection as previously
described (Gurdon et al., 1985). For protein overexpression, embryos were
injected in the animal pole with the indicated dose of mRNAs at the 2-cell stage
into both blastomeres. Animal caps were collected at stage 8–8.5 in dissociating
buffer (1X Ca2+-Mg2+ free MBS, 0.5 mM EDTA, 0.1% BSA) and cultured to
various stages according to Nieuwkoop and Faber (1967). Dissociated cells were
exposed to the indicated times and concentrations of activin (human activin A,
R&D system) and BMP (recombinant human BMP2-4, R&D system).
Constructs
The extracellular and intracellular domain of Xenopus BMPRIA (Alk3)
(residues 1–183) (GenBank accession no. D32066) was PCR amplified from the
plasmid pSP64TBX (from Suzuki) using primers (BglII-Alk3 forward primers,
5′ GAAGATCTATGAGAGAACGACTTTTCATTGCA 3′; EcoRI-Alk3 reverse
primer 5′ CGGAATTCCCTTTGGGAATGCAGTTTATG 3′). The intracellular
domain of ActRIB (ALK4) (residues 160–498) (GenBank accession no.
U60643) was PCR amplified from the plasmid BS-Xalk4 (from Hemmati-
Brivanlou) using primers (EcoRI-Alk4 forward primer 5′ CGGAATTCCCAT-
CATGTGAAATGTAT 3′; SpeI-Alk4-tagged reverse primer 5′ GGACTAGTC-
TAAGCGTAGTCTGGGACGTCGTATGGGTAGATTTTCACATCTTCTTG
3′). The resulting PCR products were introduced into the BglII-SpeI sites of the
pBluescript RN3P vector to fuse Alk3 and Alk4. The in-frame fusion was
confirmed by sequencing. In addition the HA (hemagglutinin protein from
influenza virus) epitope tag (YPYDVPDYA) has been added to the C-terminus of
the receptor sequence. GFP-tagged Smad1 was constructed inserting both a GFP
and XSmad1 (GenBank accession no. U77639) sequences in pCS107 vector
starting fromGFP-Smad2 (Bourillot et al., 2002) and pSP64TNE-XSmad1 (from
D. Melton) constructs, respectively. The product was confirmed by sequencing.RT-PCR analysis
Whole embryo and animal cap RNAs were isolated by RNeasy Mini Kit
(QIAGEN). Polymerase chain reaction with reverse transcription (RT-PCR)
assay was carried out as described (Wilson and Melton, 1994).
Western blot analysis
Embryos were homogenized in lysis buffer (10 μl per embryo) containing
20 mM Tris–HCl pH 7.4, 1 mM EDTA, 150 NaCl, 0.5% Triton X-100, 0.1 mM
PMSF and proteinase inhibitor. Lysates were centrifuged at 12,500 rpm for
10 min in a tabletop centrifuge at 4 °C. Western blotting was done according to
the standard protocols. Antibody anti-HA (SIGMA), anti-phospho-Smad2 and
anti-phospho-Smad1 (Cell Signaling), anti-Smad2 (BD Biosciences), anti-
Smad1 (Santa Cruz) and anti-GFP (Molecular Probes) were used at dilution
indicated by the company.
Confocal microscopy
Animal cap cells from embryos injected with different mRNAs were
cultured on fibronectin slide and observed by confocal microscopy. Confocal
analysis was carried out on a Nikon Eclipse TE300 coupled to a Bio-Rad
MRC1024 inverted confocal unit. The Lasersharp 2000 5.2 software (Bio-Rad)
was used for data acquisition.
Immunofluorescence
Dissociated animal cap cells were collected at stage 8, treated with BMP and
cultured on fibronectin-coated slides. Cells were fixed in 4% paraformaldehyde
and permeabilized with 0.2% Triton X-100. Cells were then blocked in blocking
buffer containing 10% horse serum and 1% BSA. Cells were incubated with
primary antibodies anti-Smad1 (Santa Cruz) and anti-phospho-Smad1 (Cell
Signaling) according to the manufacturers' protocols. Cells were washed and
then incubated with the corresponding secondary antibodies (Alexa Fluor 647
and Alexa Fluor 568). The fluorescence intensity has been measured by
“Velocity” software.
Results
Animal cap cells are competent to receive a BMP signal at the
blastula stage
In Xenopus, BMP4, BMP receptors and Smad1 are mater-
nally expressed (Faure et al., 2000; Fritz and Sheets, 2001;
Howell et al., 1999), but it is unknown when BMP signaling
starts. The phosphorylated form of Smad1 is not detected in
unfertilized eggs or embryos until stage 8 and it has not been
correlated with the onset of the gene expression (Kurata et al.,
2001; Schohl and Fagotto, 2002). Dissociated animal cap cells
were divided equally into two batches. One batch was treated at
stage 8 for 20 min with 2.0 μg/ml BMP and the other with
10 ng/ml activin. Cells were washed to remove the excess BMP
or activin and cultured until stage 12. The expression of the
BMP target genes Xvent2 and epidermal keratin shows that
cells are already competent to receive a BMP signal starting
from stage 8 (Fig. 1, lane 2). Cells maintain competence to
respond to BMP at stages 9, 10 and even at stage 11 (Fig. 1,
lanes 3, 4 and 5, respectively), when the same batch of cells has
lost the competence to express the activin-responsive gene Xbra
(data not shown) (Grimm and Gurdon, 2002). We conclude that
cells are ready to receive a BMP signal starting from stage 8
and that they maintain their BMP competence until stage 11;
Fig. 1. Dissociated animal cap cells are competent to receive a BMP signal at
stages 8, 9, 10 and 11. Dissociated animal cap cells from normal embryos were
treated for 20 min with 2 μg/ml of BMP4 at stage 8 (lane 2), stage 9 (lane 3),
stage 10 (lane 4) and stage 11 (lane 5), washed and cultured until stage 12.
RT-PCR was then carried out to test the expression of Xvent2 and epidermal
keratin. RT-PCR positive and negative samples were loaded (lanes 6 and 7,
respectively). EF1α is the loading control.
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at stage 8 since gene expression was assayed at stage 12. Cells
might bind BMP to their surface at stage 8, but not transduce the
signal until later.
BMP elicits immediate gene transcription at the blastula stage
in response to an immediate phosphorylation of Smad1
To address the question whether BMP activates gene
transcription immediately after its binding to the receptor as
early as stage 8, we checked normal embryos for Xvent2, epi-
dermal keratin and msx1 expression by RT-PCR. Cells were
first treated for 20 min with BMP and then incubated for 0.5, 2
and 4 h (Fig. 2A, left panel). All three genes were expressed
within an hour after BMP exposure (Fig. 2A, right panel) and all
three transcripts were still present after 4 h (Fig. 2A, lane 4). To
further refine the timing of ligand presentation to gene
activation we treated dissociated animal cap cells with BMP
for 5 or 20 min and incubated for shorter lengths of time (Fig.
2B). We found that 30 min after BMP exposure (20-min BMP
treatment plus 10-min incubation time) is sufficient to activate
gene expression (Fig. 2B, lane 8). We then analyzed by Western
blot the timing for Smad1 to be phosphorylated after BMP
exposure. As we saw gene expression 30 min after BMP
presentation (Fig. 2B, lane 8), we expected to detect an acti-
vated Smad1 in the same sample. Smad1 activation is only
weakly detectable in these cells (Fig. 2C, lane 2). As the
Western blot analysis does not visualize a strong activation of
Smad1, we have performed in addition an immunofluorescence
analysis to better study how quickly Smad1 is phosphorylated
(Fig. 2D). In non-BMP-treated cells, Smad1 is distributed
throughout the cytoplasm and the nucleus (Fig. 2Da) in accordwith previous reports (Xiao et al., 2001). In cells treated with
500 ng/ml BMP and incubated for 5 or 20 min (Fig. 2D, panels
d, e, f and g, h, i, respectively), we found that Smad1 is already
phosphorylated 5 min after BMP treatment (Fig. 2D, panel e)
while the rest of the pool of Smad1 remains non-phosphorylated
and mainly localized in the cytoplasm (Fig. 2D, panel f, blue
stain). In contrast, after 20 min of BMP treatment, the
cytoplasmic non-phosphorylated pool of Smad1 is converted
to the nuclear phosphorylated form, resulting in a 4.6-fold
decrease in the cytoplasmic pool (Fig. 2D, panel g and line
chart). We conclude that the phosphorylation of Smad1 is very
rapid and occurs immediately after BMP exposure.
Our results show that animal cap cells are therefore
competent to receive a BMP signal at the blastula stage and
almost immediately to initiate transcription. This is in contrast
to the response of the same cells to activin where Xbra
transcription is delayed for several hours after activin treatment
(Bourillot et al., 2002). Such a difference between immediate or
delayed transcription resulting from a cell's interpretation of
different ligands may help cells to discriminate between two
signals during development.
The state of Smad1 phosphorylation reflects the gene
expression level
Cells recognize their position in an activin morphogen
gradient by reading the concentration of extracellular ligand.
This induces the corresponding amount of Smad2 to be
phosphorylated and to migrate as a complex together with
Smad4 into the nucleus (Bourillot et al., 2002). To test if cells
use the same strategy to interpret a BMP signal, we determined
the amount of phosphorylated Smad1 in blastula cells exposed
to increasing concentrations of BMP4. Cells were treated with
increasing concentrations of BMP4 for 20 min, washed several
times to remove the excess BMP and cultured for 1 h. Xenopus
blastula cells respond to BMP at a very high concentration. We
do not know the natural concentration of any morphogen at the
time when it is effective in normal cells. It has, however, been
commonly observed that isolated cells need to be subjected to
very high concentrations of BMP to obtain a response (Wilson
and Hemmati-Brivanlou, 1995), possibly because commercial
preparations of BMP have low biological activity. Even though
a high concentration of BMP is used, this does not induce
Smad2 phosphorylation (Supplementary Fig. 1) nor the activin
downstream gene Xbra (Supplementary Fig. 2). It should also
be noted that, unlike others, we expose cells to BMP for a very
short amount of time (20 min). Continuous exposure requires a
lower BMP concentration to activate the same downstream
genes.
Fig. 3A shows that an increasing amount of extracellular
BMP corresponds to an increased percentage of phosphorylated
Smad1 in these cells. The increased phosphorylation of Smad1
is also observed by immunofluorescence analysis where dis-
sociated animal cap cells were treated with 0, 50, 500 and
2000 ng/ml BMP for 20 min and then immediately fixed (Fig.
3B). An accurate quantitation of the phospho-Smad1 fluores-
cence intensity has been done (Fig. 3C). In addition, to link the
Fig. 2. Smad1 is phosphorylated and gene transcription initiated within half an hour after BMP treatment at stage 8. (A) Immediate transcription of Xvent2, epidermal
keratin and msx1 genes is observed within an hour after the BMP treatment in normal embryos. Dissociated cells were exposed to BMP for 20 min, then washed and
cultured for the indicated length of time (left panel). Dissociated animal cap cells were incubated in the absence (lane 1) or in the presence of 2 μg/ml of BMP4 for
20 min and cultured for the times shown (right panel, lanes 2, 3 and 4). Xvent2, epidermal keratin and msx1 are expressed within an hour of BMP presentation. EF1α
is the loading control. (B) The timing of gene expression after BMP treatment. Left panel, dissociated animal cap cells were collected at stage 8, treated without BMP
(lane 1) or with 2 μg/ml BMP for 5 min (samples 2 to 5) or 20 min (samples 6 to 10) and incubated for 0 (lanes 2 and 6), 5 (lanes 3 and 7), 10 (lanes 4 and 8), 20 (lanes 5
and 9) and 30 min (lane 10). Right panel, msx1 starts to be expressed after 20 min of BMP exposure plus 5-min incubation, 30 min in total after BMP presentation
(lane 8). ODC is the loading control. (C) Western blot analysis of animal caps from normal embryos, treated with 2 μg/ml of BMP for 20 min. Five animal caps were
loaded per lane. Antibodies recognized total or phosphorylated Smad1, αSmad1 or αPSmad1, respectively. Samples were frozen 15 min (lane 2), 30 min (lane 3),
45 min (lane 4), 1 h (lane 5), 2 h (lane 6) and 4 h (lane 7) after BMP treatment. (D) Smad1 activation in Xenopus animal cap cells in the presence of BMP.
Left, dissociated animal cap cells were cultured on fibronectin coated slides, treated at stage 8 with 500 ng/ml BMP for either 5 or 20 min and immediately fixed. Cells
were then stained with anti-Smad1 and anti-phosphoSmad1 antibodies. After 20 min most of the Smad1 pool is phosphorylated and localized into the nucleus. Scale
bar, 30 μm. Right, a line chart to show changes in nuclear and cytoplasmic Smad1 over time.
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in gene expression, we checked the level of the msx1 and
Xvent1 expression (Fig. 3D). We found that the level of the
BMP target genes analyzed is affected by the amount of BMP
used.We therefore conclude that an extracellular concentration
of BMP is rapidly registered by a proportionate concentra-
tion of phospho-Smad1 in the nucleus. This concentration
is then transduced into a proportionate amount of gene
activation.
Fig. 3. Smad1 phosphorylation state reflects quantitatively the gene expression level. (A) Increasing concentrations of BMP ligand induce an increased amount of
phosphorylated Smad1. Dissociated animal cap cells were treated with different concentrations of BMP as shown. Activation of Smad1 was measured by Western blot
using anti-phospho-Smad1 antibody (α-PSmad1). The total amount of Smad1 protein has been visualized using anti-Smad1 antibody (α-Smad1). (B) The Smad1
phosphorylation level reflects the BMP concentration received by a cell. Cells were cultured on fibronectin-coated slides, treated with 0 (panels a), 50 (panel b), 500
(panel c) and 2000 (panel d) ng/ml BMP, fixed with 4% paraformaldehyde and analyzed by immunofluorescence using an antibody against the phosphorylated form of
Smad1 (α-PSmad1). Scale bar, 60 μm. (C) Quantitation of nuclear fluorescence. The average nuclear α-phospho-Smad1 fluorescence intensity of panels a–d has been
measured and is represented by bars a, b, c and d, respectively. Each bar represents the mean value±SD of the intensity of nuclear Smad1 in about 100 cells. (D) The
extent of gene expression is proportionate to BMP concentration. Animal cap cells were treated with 50 pg/ml (lane1), 1 ng/ml (lane2), 50 ng/ml (lane3), 100 ng/ml
(lane4), 500 ng/ml (lane 5) and 2000 ng/ml (lane 6) BMP or no BMP (lane 7). msx1 and Xvent1 were analyzed. ODC is the loading control.
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activated receptor
We have seen above that the expression of the genes Xvent2,
epidermal keratin and msx1 is detected within half an hour of a
brief BMP treatment and continues for 2–4 h after that. We do
not know if the sustained gene expression is due to Smad1 that,
once it is phosphorylated at the receptor level, remains for 2–4 h
in the nucleus or to the activated receptors that continuously
phosphorylate and transmit to the nucleus newly available
Smad1 molecules. To test these two hypotheses we have used
the reagent H7 (1-(5-isoquinolinesulfonyl)-2-methylpiperazine
(Engh et al., 1996; Kumahara et al., 1999)) that inhibits the
kinase domain of the BMP receptors and consequently the
phosphorylation of Smad1 to test its effect on the expression of
Xvent1, Xvent2 and msx1 in normal embryos (Fig. 4). In the
presence of the inhibitor H7, BMP target gene expression
became undetectable as soon as the inhibitor was added (Fig. 4,
lanes 3, 4 and 5). Only when the inhibitor H7 is added at stage
10, about 1 h before samples are frozen, is it possible to detect
very low gene expression (Fig. 4, lane 6). Our results show that
a continuous BMP receptor complex activity is required for
downstream gene expression. In fact, the pool of initially
phosphorylated Smad1, even before the H7 treatment, is not
sufficient to maintain gene expression; this suggests that there isa continuous turnover of Smad1 protein as has been previously
proposed for Smad2.
Thus, we conclude that continuous BMP receptor complex
activity is necessary for downstream gene expression, and that,
by such a receptor, cells continuously monitor their extra-
cellular concentration of BMP and maintain a gene response
up to 4 h.
Cloning and expression of a chimeric receptor
To understand the continuous interpretation of an extra-
cellular BMP concentration gradient, we need to visualize the
kinetics of intracellular signaling in real-time with a living
cell marker. We first followed Smad1 movement into the
nucleus immediately after BMP treatment, making use of GFP-
Smad1. We expected to find, before BMP exposure, a cyto-
plasmic localization of GFP-Smad1 or an equal distribution of
GFP-Smad1 in both the cytoplasmic and nuclear compartments
as has been seen in previous study (Liu et al., 1996). As
expected, we see a nuclear localization of GFP-Smad1 in the
presence of BMP4 (Fig. 5A, panel b). But surprisingly, GFP-
Smad1 is also concentrated in the nucleus in the absence
of BMP4 (Fig. 5A, panel a) even if this condition does
not involve any gene activation (Fig. 5B) (Xiao et al., 2001).
Therefore, GFP-Smad1 behaves differently from GFP-Smad2
Fig. 4. A continuous BMP receptor complex activity is required for maintaining
a gene response. Gene transcription is stopped in the presence of the kinase
inhibitor H7. Top panel: schematic representation of experimental design for H7
treatment. Bottom panel: dissociated animal caps from four normal embryos
were treated with 2 μg/ml BMP4 for 20 min at stage 8.5, and subsequently with
100 μM H7 as shown. Xvent1, Xvent2 and msx1 expression was analyzed by
RT-PCR. EF1α is the loading control.
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(Fig. 5A, panel c) and migrates into the nucleus only in the
presence of activin (Fig. 5A, panel d). The Smad1 shuttling
between the cytoplasm and the nucleus even when signaling is
not taking place makes the kinetic analysis of the intracellular
BMP signaling difficult to interpret. We have therefore
constructed a chimeric receptor that responds to BMP4 as an
extracellular ligand but transduces signaling inside the cell
through Smad2 which has no background of nuclear localiza-
tion in the absence of ligand. We are therefore using a Smad2 to
represent BMP rather than activin signaling.
Our chimeric receptor is composed of the extracellular and
transmembrane domains of the BMP receptor type IA (Alk3)
which is responsible for binding a BMP ligand (see Materials
and methods) (Hatta et al., 2000; Nohe et al., 2004). It also
contains the intracellular part of the activin receptor type IB
(Alk4) that has the kinase domain for Smad2 activation
(Fig. 5C). We have tested the expression of this chimeric
receptor by Western blot using an antibody against the HA
epitope tag (Fig. 5D). This chimeric receptor is abundantly
expressed both in whole embryos and in animal cap cells at
stage 11, after chimeric receptor mRNA injection at the 2-cell
stage. Increasing concentrations of injected chimeric receptor
mRNA lead to increased amounts of expressed protein in whole
embryos (Fig. 5D, lanes 1, 2, and 3). We conclude that the
injected chimeric receptor mRNA is translated and that the
corresponding protein is expressed in animal cap cells.The chimeric receptor is functional: it induces early
activin-response mesodermal genes and inhibits
BMP-responsive genes in animal cap cells
Since the chimeric receptor is expressed in animal cap cells
we can now ask whether it binds BMP and transduces BMP
signaling through Smad2. To test this idea we analyzed the
induction of known marker genes downstream of Smad2
activation such as Xbra, Gsc and Eomes after BMP4 treatment.
Control cells and BMP receptor type IA (Alk3) overexpressing
cells, because of the presence of the endogenous activin
receptors, express Xbra, Gsc and Eomes after activin but not
after BMP treatment (Fig. 6A lanes 2 and 8, respectively). As
expected, the same results are obtained with activin receptor
type I (Alk4) overexpressing cells (Fig. 6A, lane 5). Chimeric
receptor expressing cells, instead, express all three activin target
genes after BMP treatment showing that the chimeric receptor
acts through Smad2 (Fig. 6A, lane 12).
We then checked, in the same samples, the expression
of BMP-responsive genes such as Xvent1, Xvent2, msx1 and
Wnt8b that are downstream of the Smad1 signal (Fig. 6B, bars
4). The levels of Xvent1, Xvent2, msx1 and Wnt8b expression
in animal cap cells provided with chimeric receptor and BMP
were strongly inhibited in comparison with the control BMP-
treated cells that show the expected increased level of the BMP
target gene expression (Fig. 6B, compare bars 4 to bars 2).
Chimeric receptor injected cells in the absence of BMP do not
express any of the four genes analyzed, as expected (Fig. 6B,
bars 3). In conclusion, our results show that the chimeric
receptor is functional and is able to activate activin downstream
genes and inhibit BMP downstream genes.
GFP-Smad2 migrates into the nucleus after BMP treatment in
the chimeric receptor+GFP-Smad2 co-injected animal cap cells
Since we have proved that the cloned chimeric receptor
induces Smad2 target gene expression, we checked the ability of
the chimeric receptor to phosphorylate GFP-Smad2 and to cause
its translocation into the nucleus only after BMP treatment (Figs.
6C and D). First, Western blot analysis showed that both the
endogenous and exogenous GFP-Smad2 proteins are largely
phosphorylated after BMP treatment (Fig. 6C, lane 3). Second,
we followed the GFP-Smad2 nuclear translocation after BMP4
treatment by confocal microscopy. Three different mRNA
samples encoding GFP-Smad2, GFP-Smad2 with BMPRIA
(Alk3), or GFP-Smad2 with the chimeric receptor (Alk3-Alk4)
were injected into embryos at the 2-cell stage. At stage 10, cells
were treated for 10 min with 2 μg/ml of BMP4 or 10 ng/ml
activin. In an unstimulated state, in all three batches of cells,
GFP-Smad2 is localized in the cytoplasm (Fig. 6D, panels a, d
and g). After activin treatment, GFP-Smad2moves within 20 min
into the nucleus of the GFP-Smad2 overexpressing cells (Fig. 6D,
panel b). This effect is also seen in the BMPRIA mRNA injected
cap cells and in the chimeric receptor injected cap cells because
of the presence of the endogenous activin receptors (Fig. 6D,
panels e and h). However, no GFP-Smad2 migration is seen after
BMP treatment in the control GFP-Smad2 injected cells or in the
Fig. 5. GFP-Smad1 is localized in both nucleus and cytoplasm in the absence of BMP. Distribution of GFP-Smad1 in Xenopus animal cap cells. (A) 0.2 ng of GFP-
Smad1 mRNAwas injected in embryos at the 2-cell stage. Animal cap cells were isolated at stage 8 and cultured on a fibronectin slide with (panel b) or without 2 μg/ml
of BMP4 (panel a). In comparison, panels c and d show animal cap cells injected with 0.2 ng GFP-Smad2 mRNA in the absence and in the presence of 10 ng/ml
activin, respectively. Scale bar, 20 μm (B) Nuclear GFP-Smad1 does not activate gene response. Five animal caps from injected GFP-Smad1 embryos (lanes 1 to 4) and
from control embryos (lanes 5 and 6) were analyzed by RT-PCR to test the expression of msx1 and Xvent1 in the absence and in the presence of BMP treatment. ODC
represents the loading control. Samples 1 and 2 are duplicates as well as samples 3 and 4. (C) Cloning and expression of BMPRIA-ActRIB (Alk3-4). Schematic
representation of the cloned chimeric receptor. BMPRIA-ActRIB (Alk3-4) is composed of the extracellular and transmembrane domains of Xenopus BMPRIA (Alk3)
and the intracellular domain of ActRIB (Alk4). The HA epitope tag has been cloned in frame with the receptor's sequence. TMD, transmembrane domain; GSD, GS
domain; KD, kinase domain; HA, influenza virus hemagglutinin epitope tag; (number), amino acids corresponding to the BMPRIA and ActRIB sequences used for
cloning. (D) Western blot analysis of the chimeric receptor (BMPRIA/ActRIB) protein in whole embryos and in animal cap cells at stage 11. Embryos were injected at
the 2-cell stage with 1.0 ng (lane 1), 2.0 (lane 2) and 4.0 ng (lanes 3 and 4) of chimeric receptor mRNA. 10 Animal caps (lane 4) and two whole embryos (lanes 1–3)
were loaded in each lane and subjected to Western blot analysis with anti-HA antibody (α-HA).
Fig. 6. The cloned chimeric receptor is functional. (A) Induction of early mesodermal markers in chimeric receptor injected animal cap cells. Embryos were injected a
the 2-cell stage with 4 ng of mRNA encoding the activin receptor type IB (ActRIB), BMP receptor type IA (BMPRIA) and the chimera BMPRIA/ActRIB. Five anima
caps were collected at stage 8.5 and cultured to stage 10 before being treated with 2 μg/ml BMP or 10 ng/ml activin for 20 min; EF1α is the loading control; uninjected
control caps from uninjected embryos. (B) Inhibition of BMP-responsive genes in chimeric receptor injected animal cap cells after BMP4 treatment. Five animal caps
from chimeric receptor mRNA injected embryos (bar 4) and five animal caps from control embryos (bar 2) were collected at stage 8.5 and treated with 2 μg/ml BMP
for 20 min at stage 10. Five animal caps from chimeric receptor mRNA injected embryos (bar 3) and five animal caps from control embryos (bar 1) were not treated
with BMP. RT-PCR was performed to test the expression of msx1, Xvent1, Xvent2 and Wnt8b. (C) GFP-Smad2 is phosphorylated and accumulated in the nucleus in
chimeric receptor mRNA injected cells after BMP treatment. Western blot analysis of the phosphorylated form of Smad2 in the chimeric receptor+GFP-Smad2
mRNAs co-injected cells in the presence of BMP. Ten animal caps per lane were loaded and analyzed using an antibody against phospho-Smad2 (α-PSmad2). Both the
exogenous and the endogenous forms of Smad2 are detected. Smad2 (α-Smad2) was used as loading control for total protein. (D) Confocal analysis of the GFP-Smad2
nuclear translocation. Two-cell stage embryos were injected at the animal pole with the indicated constructs. The injected animal caps were collected at stage 8, treated
for 20 min with 2μg/ml of BMP or 10 ng/ml of activin at stage 10, dissociated and cultured on fibronectin slides. In the unstimulated state GFP-Smad2 was localized
in the cytoplasm (panels a, d and g). In the presence of activin, GFP-Smad2 accumulated in the nucleus (panels b, e and h). After BMP treatment only the chimeric
receptor+GFP-Smad2 mRNAs co-injected cells showed the nuclear localization of GFP-Smad2 (panel i). Scale bar, 40 μm. (E) Elongation of animal cap explants and
double axes in embryos in response to the overexpression of the chimeric receptor. Control animal caps (panels a) and 0.8 ng chimeric receptor mRNA injected caps
(panels b and c) were collected at stage 8 and cultured in 1X MBS until the stages shown. Control embryos (panel d) and 0.8 ng chimeric receptor mRNA ventrally
injected embryos at the 4-cell stage (panels e) and at the 16-cell stage (panel f) were cultured until stage 26 and analyzed for the presence of a double axis. The presence
of endogenous BMP is sufficient to induce elongation in explanted animal caps and full (panel e) or partial (panel f) double axes in embryos.
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respectively). In contrast, only the chimeric receptor BMPRIA/
ActRIB (Alk3/4)+GFP-Smad2 co-injected animal cap cells
show GFP-Smad2 in the nucleus after BMP stimulation (Fig.
6D, panel i). Our conclusion is that the chimeric receptor can be
used to study the kinetics of BMP signaling.
Overexpression of the chimeric receptor induces elongation in
injected animal caps and double axis in injected embryos
In order to further characterize the chimeric receptor activity,
we analyzed the phenotype of both chimeric receptor injectedanimal caps and injected embryos (Fig. 6E). The elongation test
in animal caps has been used in the past to identify mesoderm
inducing factors like activin (New et al., 1997; Smith and
Harland, 1991; Sokol et al., 1991). We used this test to support
the idea that the cloned receptor responds to BMP inducing
activin downstream responses. Our results show that chimeric
receptor injected animal caps have the ability to elongate in the
presence of endogenous BMP (Fig. 6E, panels b and c). The
effect of elongation does not occur in BMP type I receptor
injected animal caps (data not shown).
We then analyzed chimeric receptor injected embryos. We
expected to see the formation of a secondary axis, as a
90 I. Simeoni, J.B. Gurdon / Developmental Biology 308 (2007) 82–92consequence of the inhibition of BMP pathway (Maeno et al.,
1994; Suzuki et al., 1994). We injected embryos ventrally at
the 4-cell or 16-cell stages in a single blastomere using
different concentrations of chimeric receptor mRNA. In 55%
of the injected embryos at the 4-cell stage (11 out of 20 in
two independent experiments), in the presence of the
endogenous BMP, we observed distinct double axes (Fig.
6E, panel e) and in 58% of the injected embryos at the 16-cell
stage (14 out of 24 in two independent experiments) a partial
double axis (Fig. 6E, panel f). The rest of the embryos
presented several abnormalities. Our results confirm that the
cloned chimeric receptor inhibits the ventral fate, promoting a
dorsal fate.
The chimeric receptor detects in real-time the presence of BMP
at the plasma membrane
We have shown above that Xenopus animal cap cells are
competent to receive a BMP signal at the blastula stage but
we were not able to distinguish whether the endogenous
Smad1 localization takes place before or after the BMP
treatment because of its continuous shuttling between the
nucleus and the cytoplasm. For this reason, we made use of
the chimeric receptor to see in real-time if the GFP-Smad2
nuclear translocation and its phosphorylation immediately
follow BMP treatment of chimeric receptor+GFP-Smad2 co-
injected animal cap cells at the blastula stage. Fig. 7A shows
images from time lapse movie visualizing the nuclear
localization of GFP-Smad2 immediately after the exposure
of the cells to BMP (movie available in Supplementary
data). It is possible to see a nuclear GFP-Smad2 distribution
already after 6–8 min of BMP exposure. The phosphorylated
state of Smad2 is then maintained for up to 4 h (Fig. 7B,
lane 4). We have used our chimeric receptor to determine
quantitative aspects of BMP signaling and interpretation. We
analyzed the amount of the phosphorylated form of GFP-
Smad2 in chimeric receptor+GFP-Smad2 co-injected animal
cap cells using increasing concentrations of extracellular
BMP. We found that increasing the amount of extracellular
BMP4 corresponds to an increased percentage of phosphory-
lated GFP-Smad2 in the nucleus (Fig. 7C). This result is
also confirmed by confocal microscopy in which the
intensity of the GFP-Smad2 fluorescence in the nucleus
increases in the presence of a higher concentration of BMP
(Fig. 7D).
These results, together with those obtained with the endo-
genous BMP receptor and Smad1 (see Fig. 3A), show that the
interpretation of BMP concentration outside a cell depends
entirely on the extracellular domain of the BMP receptor
complex; while the other components of signaling pathways
might be necessary, they do not have an effect on the
quantitative interpretation of BMP concentration.
Discussion
We have analyzed how cells interpret BMP signaling at a
very early stage in Xenopus development.Cell competence to discriminate between different signals
Cells are able to respond to different TGF-β signals at
different times during development. For example, cells are
competent to receive an activin signal between stages 8 and 11
before losing their competence to respond to activin at the
gastrula stage. This loss of competence correlates with the
inability of Smad2 to accumulate in the nucleus. However, the
ability to respond to activin is then reacquired at stage 20
suggesting a reiterative usage of the same signaling pathway at
different stages of development (Grimm and Gurdon, 2002). It
has recently been shown that the loss of competence to activin
can be delayed by Notch signaling. Notch activation enables
Smad2 to form a complex with Smad4 and to accumulate in the
nucleus even after stage 11 (Abe et al., 2005). In contrast to
what we observed with activin, we find that cells are competent
to receive a BMP signal at all stages, from the blastula to the late
gastrula stage. We suggest that the duration of competence,
which differs for BMP and activin, is a mechanism which helps
Xenopus cells to discriminate among a variety of signals
received at the same time. A second difference between BMP
and activin is that BMP stimulates immediate gene transcrip-
tion. In contrast, the activin response is delayed until the
beginning of the gastrula stage even if exposure to the activin
signal happened at the blastula stage (Bourillot et al., 2002;
Jullien and Gurdon, 2005). The activin ligand/activin receptor
complex is rapidly internalized and the time for which the
complex remains in the endo-lysosomal pathway is the basis for
memory of the activin signal (Jullien and Gurdon, 2005).
Further studies have provided important details of the relation-
ship between receptor trafficking and signaling in the TGF-β
signal transduction pathways but very little insight is so far
available for a similar relationship in the BMP signaling
pathway (Hartung et al., 2006; Le Roy and Wrana, 2005). To
explain why cells express downstream genes immediately after
BMP signaling and why they do not delay gene expression as
activin does, we suggest that once internalized, the BMP
receptor/BMP ligand complex is no longer kept in the endo-
lysosomal pathway, but the complex is immediately degraded.
Intracellular response
The accumulation of Smad2 in the nucleus only after activin
treatment represents a mechanism by which cells recognize their
position in the morphogen gradient (Bourillot et al., 2002). In
our present results, in the absence of BMP, Smad1 is partially
localized in the nucleus but this event is not related to active
gene expression, in accord with a previous study (Xiao et al.,
2001). This indicates the presence of a pool of non-
phosphorylated Smad1 proteins shuttling between the cytosol
and the nucleus. By contrast, in the presence of BMP, Smad1
rapidly accumulates in the nucleus and the amount of
phosphorylated Smad1 increases in relation to the amount of
BMP ligand present extracellularly. The concentration of
nuclear Smad1 leads to a proportionate level of gene activation.
Thus, we find that the mechanism by which cells respond to the
BMP signal is in this respect shared with that needed to interpret
Fig. 7. The chimeric receptor can detect in real-time the presence of BMP. (A) Confocal time course analysis of dissociated animal cap cells from chimeric receptor+
GFP-Smad2 co-injected embryos after BMP treatment. Animal cap cells were treated directly at the confocal with 2 μg/ml of BMP4 at stage 8 and immediately
analyzed. Pictures were taken every 2 min. Scale bar, 40 μm. (B) Western blot analysis of animal caps from embryos co-injected with GFP-Smad2+chimeric receptor
mRNAs. Ten animal caps were loaded in each lane and treated with 2 μg/ml of BMP for 10 min. Samples were frozen 1 h (lane 2), 2 h (lane 3) and 4 h (lane 4) after
BMP treatment. Anti-phospho-Smad2 antibody recognizes both the exogenous GFP-Smad2 (upper bands) and endogenous form of Smad2 (lower bands).
(C) Increasing concentrations of BMP ligand induced an increased amount of phosphorylated GFP-Smad2. Animal cap cells from chimeric receptor+GFP-Smad2 co-
injected embryos were treated with 0, 50, 100, 600,1200 and 4000 ng/ml of BMP4. Activation of Smad2 was visualized by Western blot using anti-phospho-Smad2
antibody (α-PSmad2). The total amount of Smad2 protein has been visualized using anti-Smad2 antibody (α-Smad2). (D) Dissociated animal cap cells from chimeric
receptor+GFP-Smad2 mRNAs co-injected embryos were cultured on fibronectin coated slides and treated with the indicated amount of BMP for 20 min. GFP-Smad2
dissociated animal cap cells were also treated with activin for the same length of time. Cells were then washed and analyzed by confocal microscopy. The intensity of
the nuclear GFP-Smad2 fluorescence (black bars) and cytoplasmic GFP-Smad2 fluorescence (white bars) have been measured by arbitrary units using the “Laser
Sharp” program and represented as bars in the graphic (left panel). Each bar represents the mean value±SD of the intensity of nuclear GFP in about 100 cells analyzed
from two independent experiments. Representative group of cells for each experiment is shown (right panels). Scale bar, 20 μm.
91I. Simeoni, J.B. Gurdon / Developmental Biology 308 (2007) 82–92an activin signal. We also find that the signal can persist for 4 h,
even after a short exposure to BMP, due to the presence of a
continuously activated BMP receptor complex at the plasma
membrane. This result shows another shared mechanism
between the activin and BMP signaling pathways. Therefore,
in spite of the considerable differences between activin and
BMP signaling, some characteristics of signal interpretation
apply to both pathways and may represent general principles of
TGF-β signal interpretation.
Our results elucidate differences and similarities between
BMP and other signaling pathways of the TGF-β family. Thuswe ask, how does a cell make a decision to follow a BMP signal
instead of another? If we compare BMP and activin signaling,
previous work has proposed that Smad4 is the limiting factor and
is able to give priority to an activin signal so that it is transduced
instead of the BMP signal (Candia et al., 1997). As happens
during hematopoiesis, in which each hematopoietic lineage is
specified by lineage-restricted transcription factors, we spec-
ulate that this also happens for the intracellular transducer Smads
during early development. Having demonstrated a correlation
between the nuclear Smad concentration and the extent of gene
expression, we support the idea that higher concentrations of
92 I. Simeoni, J.B. Gurdon / Developmental Biology 308 (2007) 82–92nuclear Smad2 and 3 than of Smad1, 5 or 8 would determine a
dorsal mesodermal fate instead of a ventral fate.
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